Strength Seen in IntelliPharmaCeutics (IPCI): Stock Shoots 161.9%

Zacks Equity Research
November 20, 2013

IntelliPharmaCeutics International Inc. (IPCI) was a big mover last session, as the company saw its shares shoot by nearly 162% on the day. The move came on solid volume too with far more shares changing hands than in a normal session as the company gained the U.S. Food and Drug Administration’s approval to market the generic version of attention deficit hyperactive disorder drug, Focalin XR. The closing price represents a substantial jump from the near-flat trading range of $1.68 to $2.00 in the past one-month time frame.

This biopharmaceutical company has seen no estimate revisions in the past 30 days and its Zacks Consensus Estimate has remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

IntelliPharmaCeutics currently has a Zacks Rank #3 (Hold) and its Earnings ESP is 0.00%.

Some better performing stocks in the same industry include Lannett Company, Inc. (LCI), Jazz Pharmaceuticals Public Limited Company (JAZZ) and Furiex Pharmaceuticals, Inc. (FURX). While Lannett and Jazz carry a Zacks Rank #1 (Strong Buy), Furiex carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


INTELLIPHARMACEUTICS INTERNATION (IPCI): Free Stock Analysis Report

LANNETT CO INC (LCI): Free Stock Analysis Report

FURIEX PHARMACEUTICALS INC (FURX): Free Stock Analysis Report

JAZZ PHARMACEUTICALS PLC IRELAND (JAZZ): Free Stock Analysis Report


Zacks Investment Research